Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine

Anti-Cancer Drugs

Volumn 17, Issue 10, 2006, Pages 1185-1191

  Pappas, Periklis ^a   Mavroudis, Dimitris ^b   Nikolaidou, Martha ^a   Georgoulias, Vassilis ^b   Marselos, Marios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Gemcitabine; Interaction; Oxaliplatin; Pharmacokinetics; Solid tumors

Indexed keywords

DEXAMETHASONE; DIAZEPAM; GEMCITABINE; ONDANSETRON; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATOMIC ABSORPTION SPECTROMETRY; BLADDER CARCINOMA; BLOOD TOXICITY; BREAST TUMOR; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM; TREATMENT OUTCOME;

EID: 33750554489     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000236303.97467.49     Document Type: Article

References (31)

1. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 1990; 38:567-572.
2. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
3. Carmichael J. The role of gemcitabine in the treatment of other tumors. Br J Cancer 1998; 78:S21-S25.
4. Green M. Gemcitabine safety overview. Semin Oncol 1996; 23:S32-S35.
5. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:310-316.
6. Raymond E, Faivre S,Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:S4-S12.
7. Cvitkovic E. Ongoing and unsaid on oxaloplatin: the hope. Br J Cancer 1998; 77:S8-S11.
8. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44:117-123.
9. Airoldi M, Cattel L, Passera R, Pedani F, Milla P, Zanon C. Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas 2006; 32:44-50.
10. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339-1343.
11. Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer 2005; 93:29-34.
12. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13:1479-1489.
13. Gan HK, Mitchell PL, Galettis P, Davis ID, Cebon J, de Souza P, et al. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemother Pharmacol 2006; 58:157-164.
14. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22:108-114.
15. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512-1518.
16. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003; 14:304-312.
17. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, et al. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 2004; 67:376-381.
18. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
19. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-498.
20. Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999; 17:1751-1759.
21. Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administrated weekly to patients with advanced cancer. Cancer Chemother Pharmacol 2001; 48:95-103.
22. De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, et al. Phase I pharmacokinetic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2000; 11:821-827.
23. Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 2001; 12:1553-1559.
24. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6:1205-1218.
25. Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 2000; 45:157-164.
26. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25:S13-S22.
27. Kern W, Braess J, Bottger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res 1999; 5:761-765.
28. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
29. de Lange SM, van der Born K, Kroep JR, Jensen HA, Pfeiffer P, Cleverly A, et al. No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol 2005; 61:843-849.
30. van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10:441-448.
31. Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, et al. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anticancer Drugs 2005; 16:1029-1036.